SCHEMBL4873848

SCHEMBL4873848

Cc1c(F)c(F)cc(NC(=O)Nc2ccc(-n3c(C)nc4c(N)ncnc43)cc2)c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 2/20 0.48
PI4K2B Q8TCG2 2/20 0.48
PI4K2A Q9BTU6 2/20 0.48
PI4KB Q9UBF8 2/20 0.48
PTK2 Q05397 1/20 0.42
PTK2B Q14289 1/20 0.42
KDR P35968 8/20 0.40
TEK Q02763 5/20 0.40
CSF1R P07333 5/20 0.39
AURKA O14965 4/20 0.39
LCK P06239 3/20 0.39
KIT P10721 3/20 0.39
FLT3 P36888 3/20 0.39
AURKB Q96GD4 3/20 0.39
FLT1 P17948 3/20 0.39
RET P07949 2/20 0.39
MAP4K4 O95819 2/20 0.39
AXL P30530 2/20 0.39
GSK3B P49841 2/20 0.39
BLK P51451 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4877521 0.79 PI4KA (0.45) PI4KAPI4K2BPI4K2API4KBPTK2
SCHEMBL4873824 0.78 EPHB4 (0.56) PI4KAPI4K2BPI4K2API4KBPTK2
SCHEMBL3532354 0.77 PTK2 (0.66) PTK2PTK2BFLT3
SCHEMBL3536548 0.75 PTK2 (0.74) PTK2PTK2B
SCHEMBL3530565 0.74 PTK2 (0.67) PTK2PTK2B
SCHEMBL3532285 0.74 PTK2 (0.67) PTK2PTK2BNTRK2
SCHEMBL3536896 0.73 PTK2 (0.46) PI4KAPI4K2BPI4K2API4KBPTK2
SCHEMBL3528532 0.73 PTK2 (0.65) PTK2PTK2BKIT
SCHEMBL3531554 0.72 PTK2 (0.64) PTK2PTK2B
SCHEMBL3534336 0.71 PTK2 (0.61) PTK2PTK2BKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214582-A1 Purine Derivatives as Inhibitors of Receptor Tyrosine Kinase Activity MERCK PATENT GMBH (DE) 2008-09-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214582-A1 Purine Derivatives as Inhibitors of Receptor Tyrosine Kinase Activity TIE1, FLT1, RET PI4KA 457/4885PI4K2B 620/4885PI4K2A 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.